HIV is an RNA virus. Each viral particle carries two copies of a single-stranded RNA genome, making it an RNA virus by the standard classification systems used in virology.1PubMed Central. Human Immunodeficiency Virus (HIV) But calling HIV “just” an RNA virus undersells what makes it so unusual and so difficult to eliminate. HIV belongs to the retroviruses, a family of viruses that convert their RNA into DNA inside a host cell and then stitch that DNA directly into the cell’s own chromosomes. This dual life, existing as RNA in one phase and DNA in another, is what makes HIV both fascinating to study and stubbornly hard to cure.
What Makes HIV a Retrovirus
HIV belongs to the family Retroviridae, genus Lentivirus. In the formal Baltimore classification system, which groups viruses by how they handle their genetic material, HIV falls into Group VI: single-stranded RNA viruses with a DNA intermediate.2Molecular Medical Microbiology. Classification of medically important viruses That “DNA intermediate” part is what separates retroviruses from the other RNA viruses you might have heard of, like influenza or SARS-CoV-2, which replicate their RNA genomes without ever converting them to DNA.
The mature HIV particle, or virion, packages its genome as two copies of single-stranded RNA in a dimeric arrangement. Proper packaging of this dimeric RNA genome is an essential step in the virus’s replication cycle.3PubMed Central. The conformation of the mature dimeric human immunodeficiency virus type 1 RNA genome requires packaging of pol protein Having two copies may sound redundant, but it gives the virus a backup template and allows genetic recombination during the copying process, which contributes to HIV’s extraordinary genetic diversity.
How HIV Turns Its RNA Into DNA
The defining trick of any retrovirus is reverse transcription: using an enzyme called reverse transcriptase to build a DNA copy from an RNA template. When HIV infects a cell, its reverse transcriptase reads the viral RNA and assembles a double-stranded DNA version of the genome. This process involves multiple steps, including strand-transfer reactions where the enzyme switches between templates and ribonuclease activities that strip away the original RNA as the new DNA strand is built.4PubMed. Mechanism of DNA strand transfer reactions catalyzed by HIV-1 reverse transcriptase
When the discovery of reverse transcriptase was announced in 1970 by Howard Temin and David Baltimore, it was considered a major paradigm shift. The prevailing assumption at the time was that genetic information flowed strictly from DNA to RNA to protein, never the other way around. Temin had proposed years earlier that retroviruses must replicate through a DNA intermediate he called the “provirus,” but the idea was widely dismissed. The simultaneous demonstration by both labs that retroviral particles contained an enzyme capable of copying RNA into DNA convinced the scientific community almost overnight.5PubMed Central. 50th anniversary of the discovery of reverse transcriptase Both researchers received the Nobel Prize for the work.
Integration Into Human Chromosomes
Once HIV’s reverse transcriptase finishes building the double-stranded DNA copy, a second virus-encoded enzyme called integrase takes over. Integrase catalyzes the covalent insertion of that viral DNA into the host cell’s own chromosomes, creating what is called a provirus.6PubMed Central. HIV DNA integration At this point, the viral genetic material is literally part of your DNA. Every time the cell divides, it copies the provirus right along with the rest of its genome and passes it to both daughter cells.
Integration is not random. Studies mapping thousands of HIV integration sites in human cells have found that about 69% land inside active genes, a dramatic departure from what you would expect by chance. Gene-dense regions and gene-rich chromosomes are strongly favored.7Cell. Distribution of HIV-1 Integration Sites in Human DNA and in Accession Control Sequences This preference appears to be guided by host proteins, particularly a factor called LEDGF, that the integrase enzyme binds to at actively transcribed gene regions. Experimental mutations in the integrase protein can dramatically change this targeting. A single amino acid change in integrase, for instance, redirected integration more than tenfold toward centromeric repeat sequences instead of active genes.8Nature Communications. A point mutation in HIV-1 integrase redirects proviral integration into centromeric repeats
The preference for active genes is not an accident. Once embedded in an active gene, the provirus can hijack the cell’s own transcription machinery. HIV relies on the host’s RNA polymerase II to transcribe its genome, using multiple transcription start sites to generate different RNA transcripts needed for various stages of its lifecycle.9PubMed Central. HIV-1 usurps transcription start site heterogeneity of host RNA polymerase II to maximize replication fitness The virus also recruits specific human cofactors to its regulatory region, called the long terminal repeat, to drive efficient production of new viral RNA.10PubMed Central. Mechanism and factors that control HIV-1 transcription and latency activation
Why the RNA-to-DNA Lifecycle Drives Extreme Mutation
HIV’s reverse transcriptase is famously sloppy. Unlike the enzymes that copy your own DNA, which have built-in proofreading mechanisms, HIV’s reverse transcriptase has no error-correction ability. Early measurements estimated roughly five to ten errors per HIV genome per round of replication.11PubMed. Fidelity of HIV-1 reverse transcriptase Separate work examining a particularly variable region of the viral envelope gene found an error rate of about one misincorporation per 5,000 bases copied, which translates to multiple mutations per genome per cycle.12PubMed. Fidelity of HIV-1 reverse transcriptase copying a hypervariable region of the HIV-1 env gene
In living patients, the picture is even more complicated. The host’s own antiviral defenses contribute mutations on top of what reverse transcriptase introduces. A family of host enzymes called APOBEC3 proteins, which are part of the cell’s innate immune response, deliberately introduce mutations into the viral DNA during reverse transcription. In viral DNA sequences recovered from patient blood cells, APOBEC3G alone accounted for about 88% of the total mutation burden, while reverse transcriptase errors contributed roughly 2%. The observed reverse transcriptase mutation rate in both the DNA and plasma RNA sequences was nearly identical, around 6 × 10⁻⁵ per base.13PLOS Biology. Extremely High Mutation Rate of HIV-1 In Vivo Many of the APOBEC3-edited genomes are so heavily damaged they never produce viable virus, but the overall effect is a cloud of viral diversity circulating in every infected person.
This mutation rate is one reason HIV has been so difficult to control with vaccines. The virus can shift its surface proteins faster than the immune system can adapt. By comparison, SARS-CoV-2, another RNA virus, accumulates mutations at a slower pace. Both viruses use single nucleotide mutations, insertions, deletions, and recombination, but HIV-1’s extraordinary diversity far outstrips what coronaviruses generate.14PubMed Central. HIV-1 and SARS-CoV-2: Patterns in the evolution of two pandemic pathogens
The Latent Reservoir and Why Integration Makes a Cure So Hard
Antiretroviral therapy can suppress HIV replication to undetectable levels in the blood, but it cannot eliminate the virus. The reason traces directly to integration. A small pool of cells carrying integrated, replication-competent proviral DNA persists even during years of fully suppressive treatment. This was originally described as primarily a population of resting memory CD4+ T cells.15PubMed Central. HIV persistence in subsets of CD4+ T cells: 50 shades of reservoirs Because these cells are long-lived and divide occasionally, passing the provirus to their progeny, the integrated DNA can persist for decades.
The reservoir turns out to be more varied than first thought. Researchers have found intact proviruses in phenotypically naive T cells as well as multiple memory T cell subsets, and sequencing of more than 1,900 proviruses has helped estimate the contribution of each subset over time on treatment.16PubMed Central. Persistence of an intact HIV reservoir in phenotypically naive T cells More recent work has also found that cells outside the classical T cell compartment may influence reservoir size. Single-cell analyses, for example, have linked monocyte gene expression patterns to reservoir size, suggesting that the interplay between the immune system’s innate and adaptive arms affects how many infected cells persist.17PubMed Central. Single-cell analyses identify monocyte gene expression profiles that influence HIV-1 reservoir size in acutely treated cohorts
This is the central paradox of HIV’s classification. The virus enters a cell as RNA, lives for a time as DNA woven into your chromosomes, and then re-emerges as RNA when conditions are right. The DNA form is what makes a true cure so elusive: you cannot simply clear viral RNA from the blood and call it done, because the integrated DNA sits silently in cells the immune system cannot see.
How HIV’s Dual Nature Shapes Drug Treatment
Almost every class of antiretroviral drug exploits a step that exists only because HIV is a retrovirus. Reverse transcriptase inhibitors, the backbone of modern HIV treatment and prevention, directly target the enzyme responsible for converting RNA to DNA.18PubMed Central. Approved HIV reverse transcriptase inhibitors in the past decade Integrase inhibitors block the step where that newly made DNA gets inserted into the host genome. Protease inhibitors prevent the assembly of new mature viral particles. Entry inhibitors stop the virus from attaching to and entering the cell in the first place.
Drug resistance remains a persistent challenge, again because of the error-prone reverse transcriptase. A single round of replication can generate mutant viruses that are partially resistant to a given drug, which is why combination therapy using multiple drug classes simultaneously has been the standard of care for decades. Researchers continue looking for compounds that can hit more than one target at once: one recent study, for example, identified a molecule that blocked both integrase and reverse transcriptase activity.19PubMed. Zinc C293 as a novel scaffold with dual activity against HIV-1 integrase and reverse transcriptase
Detecting the Virus at Each Stage
HIV’s existence in both RNA and DNA forms also has practical implications for diagnostic testing. Standard screening tests look for antibodies or antigens, but confirmatory and research-grade tests can target either the viral RNA in plasma or the proviral DNA embedded in cells. A comparative study testing 215 samples with four different methods found that DNA quantification achieved perfect sensitivity and specificity, while RNA quantification came very close. Antibody-based ELISA also performed well, though with slightly lower specificity. RNA qualitative testing, interestingly, had notably lower specificity despite high sensitivity.20British Journal of Biomedical Science. Nucleic acid testing-optimized HIV diagnostic algorithms: a multimethod comparative effectiveness analysis in clinical practice
In clinical practice, the distinction between RNA and DNA tests matters in specific situations. Viral load monitoring, which tracks how well treatment is working, measures HIV RNA in the blood. Reservoir studies, which aim to understand the hidden pool of infected cells, often measure HIV DNA instead. Newborn screening presents another case where the difference is relevant: maternal antibodies cross the placenta and can produce false positives on antibody tests, making nucleic acid-based methods the preferred approach for diagnosing infants.
Where HIV Came From
HIV-1 arose from simian immunodeficiency viruses that naturally infect wild chimpanzees and gorillas in west central Africa. Phylogenetic analyses have identified at least four independent cross-species transmission events from primates to humans, with one or two of those possibly having occurred via gorillas as intermediate hosts.21PubMed Central. The evolution of HIV-1 and the origin of AIDS Most of these transfers produced viruses that spread only to a limited extent in human populations. The exception was one transmission involving a chimpanzee virus from southeastern Cameroon, which gave rise to HIV-1 group M, the lineage responsible for the global pandemic.22PubMed Central. Origins of HIV and the AIDS pandemic
All of these primate lentiviruses share the same retroviral lifecycle: RNA genome, reverse transcription, integration. The machinery for converting RNA to DNA and inserting it into host chromosomes is ancient, predating HIV by millions of years.
Retroviruses Already in Your DNA
That ancient history left a mark. Roughly 8% of the human genome consists of sequences derived from retroviruses that integrated into the germline cells of our ancestors and were then passed down through generations. These human endogenous retroviruses, or HERVs, are essentially fossilized remnants of infections that happened millions of years ago.23PubMed Central. Human endogenous retroviruses Most have accumulated so many mutations over time that they can no longer produce functional virus, but some have been co-opted by the human body for useful purposes. The protein syncytin, which is essential for placenta formation, originated from an endogenous retrovirus envelope gene. HIV itself does not integrate into germline cells in a way that would be inherited, but the broader retroviral strategy of RNA-to-DNA-to-host-chromosome is the same one that seeded these ancient sequences into our genome.
HIV’s Machinery Repurposed for Medicine
The same integration ability that makes HIV so dangerous has been engineered into a powerful medical tool. Lentiviral vectors, derived from HIV but stripped of all disease-causing genes, are used to deliver therapeutic genes into patient cells. Third-generation, self-inactivating lentiviral vectors have been used in clinical trials to correct genetic blood disorders and primary immunodeficiencies by inserting functional gene copies into a patient’s own stem cells.24Leukemia. Clinical use of lentiviral vectors
The technology has become especially prominent in cancer immunotherapy. Chimeric antigen receptor (CAR) T-cell therapies, which reprogram a patient’s immune cells to recognize and kill cancer, are frequently manufactured using lentiviral vectors. Several FDA-approved therapies now rely on this approach for treating conditions ranging from blood cancers to beta thalassemia and sickle cell disease.25PubMed Central. Adaptation of lentiviral vectors for viral gene therapy and their impact on host cell biology The irony is hard to miss: the same mechanism that allows HIV to permanently alter human cells is now being used to permanently fix them.